AEGLEA BIOTHERAPEUTICS INC
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.
Buy US stocks in Australia starting with AGLE. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in AGLE
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.